230 related articles for article (PubMed ID: 35668937)
1. Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine.
Dini G; Tulli E; Dell'Isola GB; Mencaroni E; Di Cara G; Striano P; Verrotti A
Front Pharmacol; 2022; 13():832929. PubMed ID: 35668937
[TBL] [Abstract][Full Text] [Related]
2. Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.
Frampton JE
Drugs; 2023 Jul; 83(10):923-934. PubMed ID: 37316680
[TBL] [Abstract][Full Text] [Related]
3. Fenfluramine for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome.
Balagura G; Cacciatore M; Grasso EA; Striano P; Verrotti A
CNS Drugs; 2020 Oct; 34(10):1001-1007. PubMed ID: 32875491
[TBL] [Abstract][Full Text] [Related]
4. Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice.
Wirrell EC; Lagae L; Scheffer IE; Cross JH; Specchio N; Strzelczyk A
Epilepsia Open; 2024 Jul; ():. PubMed ID: 38962968
[TBL] [Abstract][Full Text] [Related]
5. Evaluating fenfluramine hydrochloride as an oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome.
Besag FMC; Vasey MJ; Chin RFM
Expert Rev Neurother; 2024 Mar; 24(3):235-249. PubMed ID: 38315124
[TBL] [Abstract][Full Text] [Related]
6. Fenfluramine for the treatment of status epilepticus: use in an adult with Lennox-Gastaut syndrome and literature review.
Strzelczyk A; Becker H; Tako L; Hock S; Hattingen E; Rosenow F; Mann C
Neurol Res Pract; 2024 Feb; 6(1):10. PubMed ID: 38383582
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine.
Dini G; Tulli E; Dell'Isola GB; Mencaroni E; Di Cara G; Striano P; Verrotti A
Front Pharmacol; 2022; 13():1116575. PubMed ID: 36686669
[TBL] [Abstract][Full Text] [Related]
8. Fenfluramine for treatment-resistant epilepsy in Dravet syndrome and other genetically mediated epilepsies.
Sullivan J; Simmons R
Drugs Today (Barc); 2021 Jul; 57(7):449-454. PubMed ID: 34268532
[TBL] [Abstract][Full Text] [Related]
9. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D
Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
Zhang L; Li W; Wang C
Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
[TBL] [Abstract][Full Text] [Related]
12. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
14. Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know.
Odi R; Invernizzi RW; Gallily T; Bialer M; Perucca E
Pharmacol Ther; 2021 Oct; 226():107866. PubMed ID: 33895186
[TBL] [Abstract][Full Text] [Related]
15. A review of fenfluramine for the treatment of Dravet syndrome patients.
Simon K; Sheckley H; Anderson CL; Liu Z; Carney PR
Curr Res Pharmacol Drug Discov; 2022; 3():100078. PubMed ID: 34988433
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
Chen JW; Borgelt LM; Blackmer AB
Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
[TBL] [Abstract][Full Text] [Related]
17. Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome.
Polster T
Epilepsy Behav; 2019 Feb; 91():99-102. PubMed ID: 30269941
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Fenfluramine in Epilepsy: A Systematic Review and Meta-analysis.
Tabaee Damavandi P; Fabin N; Giossi R; Matricardi S; Del Giovane C; Striano P; Meletti S; Brigo F; Trinka E; Lattanzi S
Neurol Ther; 2023 Apr; 12(2):669-686. PubMed ID: 36853503
[TBL] [Abstract][Full Text] [Related]
19. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Selective 5-HT
Silenieks LB; Carroll NK; Van Niekerk A; Van Niekerk E; Taylor C; Upton N; Higgins GA
ACS Chem Neurosci; 2019 Jul; 10(7):3284-3295. PubMed ID: 31082204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
